Melanoma Oncological

Melanoma is a malignant tumor arising from melanocytes, the pigment-producing cells primarily located in the basal layer of the epidermis. While it represents a small percentage of skin cancer cases, it is the most aggressive form, responsible for the vast majority of skin cancer-related deaths due to its high propensity for early metastasis.

The etiology is multifactorial, involving the interaction of host genetics and environmental UV radiation exposure. Chronic or intermittent intense (blistering) UV exposure causes DNA damage, specifically cyclobutane pyrimidine dimers, leading to mutations in tumor-suppressor genes (e.g., CDKN2A, TP53) and oncogenes (e.g., BRAF, NRAS).

Melanocytes undergo malignant transformation, leading to uncontrolled proliferation. The progression typically follows the "Clark’s levels" or Breslow thickness model, characterized by an initial radial growth phase followed by a vertical growth phase. Vertical growth allows cells to invade the dermis, access lymphatic and vascular channels, and metastasize to regional lymph nodes and distant organs.

Melanoma incidence has steadily increased over the last four decades. It is more prevalent in populations with fair skin (Fitzpatrick types I and II). Globally, it is most common in Australia, New Zealand, and North America. It affects both genders, though men show higher mortality rates.

• Excessive UV radiation (sunlight/tanning beds)
• History of blistering sunburns
• Fair complexion/red hair/blue eyes
• Presence of dysplastic nevi
• Family history of melanoma
• Immunosuppression
• Genetic mutations (e.g., BRAF V600E)

A. Early Symptoms

• Asymmetry of a mole


• Irregular borders


• Variation in color (variegation)


• Diameter >6mm B. Common Symptoms


• Pruritus within a lesion


• Change in size, shape, or elevation


• Ulceration or bleeding C. Advanced Symptoms


• Palpable lymphadenopathy


• Unexplained weight loss


• Bone pain (metastatic)


• Neurological deficits (brain metastases) D. Emergency Symptoms


• Hemoptysis (pulmonary metastasis)


• Seizures (intracranial metastasis)


• Acute bowel obstruction

Inspection often reveals the "ABCDE" criteria (Asymmetry, Border, Color, Diameter, Evolving). Palpation of lymph nodes is crucial for regional staging. Dermoscopy may reveal atypical pigment networks, blue-white veils, or streaks.

A. Clinical Assessment: Full-body skin exam and lymph node palpation.
B. Laboratory Testing: Baseline LDH (prognostic marker).
C. Imaging Studies: PET/CT for staging.
D. Functional Tests: Not applicable.
E. Biopsy Findings: Excisional biopsy is the gold standard.
F. Genetic Testing: BRAF, NRAS, and c-KIT mutation analysis.
G. Differential Diagnosis: Basal cell carcinoma, seborrheic keratosis, hemangioma.

Test Name: Serum Lactate Dehydrogenase (LDH)
Type: Blood Test
Purpose: Staging/Prognosis
Expected Findings: Elevated levels in stage IV
Interpretation: Correlates with tumor burden and poor prognosis.

• PET/CT: Used for systemic staging to detect occult metastatic disease.
• Brain MRI: Recommended for symptomatic patients or high-stage disease to rule out cerebral involvement.

• Pigmented Basal Cell Carcinoma: Differentiated via biopsy.
• Seborrheic Keratosis: Often appears "stuck on"; lacks irregular borders.
• Dysplastic Nevi: Requires monitoring or excision if evolving.

• Lymphedema (post-lymph node surgery)
• Distant organ metastasis (brain, lung, liver, bone)
• Chronic pain

A. Lifestyle Modifications: UV protection, limiting sun exposure.
B. Preventive Measures: Broad-spectrum SPF, avoiding solariums.
C. Medical Treatment:

• BRAF/MEK Inhibitors: Dabrafenib/Trametinib (target BRAF mutation).


• Checkpoint Inhibitors: Pembrolizumab, Nivolumab (PD-1 inhibitors).

Prognosis is highly dependent on Breslow thickness at diagnosis. 5-year survival for localized melanoma exceeds 95%, while metastatic disease survival remains significantly lower, though improving with immunotherapy.

Primary: Sunscreen use, protective clothing.
Secondary: Annual dermatological screening.

The following homeopathic remedies have been historically indicated for symptoms associated with Melanoma Oncological. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

🔬 Lab Report Analyzer (Diagnostic Verification)

Upload your laboratory bloodwork PDF or paste your report text to automatically extract markers, detect units, and identify reference range variances related to Melanoma Oncological.